In the last trading session, 1,024,540 shares of the Kintara Therapeutics, Inc.(NASDAQ:KTRA) were traded, and its beta was 1.66. Most recently the company’s share price was $2.39, and it changed around $0.08 or 0.03% from the last close, which brings the market valuation of the company to $73.2 Million. KTRA currently trades at a discount to its 52-week high of $3.35, offering almost -40.17% off that amount. The share price’s 52-week low was $0.38, which indicates that the current value has risen by an impressive 84.1% since then. We note from Kintara Therapeutics, Inc.’s average daily trading volume that its 10-day average is 1.27 Million shares, with the 3-month average coming to 1.1 Million.
Kintara Therapeutics, Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 2. If we narrow it down even further, the data shows that none out of 3 analysts rate the stock as a Sell; another but none rate it as Overweight. Among the rest, no body recommended KTRA as a Hold, whereas 3 deemed it a Buy, and no one rated it as Underweight. Kintara Therapeutics, Inc. is expected to report earnings per share of -$0.16 for the current quarter.
Kintara Therapeutics, Inc. (NASDAQ:KTRA): Trading Information
Instantly KTRA has showed a green trend with a performance of 3.46% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of $2.63- on Wednesday, Feb 17 increased the stock’s daily price by 9.13%. The company’s shares are currently up 0.87% year-to-date, but still down -0.0363 over the last five days. On the other hand, Kintara Therapeutics, Inc. (NASDAQ:KTRA) is 0.27% up in the 30-day period. We can see from the shorts that 596.96 Million shares have been sold at a short interest cover period of 542.69 day(s).
The consensus price target as assigned by Wall Street analysts is $5.5, which translates to bears needing to increase their stock price by 130.13% from its current value. Analyst projections state that KTRA is forecast to be at a low of $4 and a high of $7. In order for the stock price to hit the forecast high, the stock would need to surge +192.89% from its current level, while the stock would need to crash 67.36% from its current level to reach the projected low.
Kintara Therapeutics, Inc. (KTRA) projections and forecasts
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 28.2%. Kintara Therapeutics, Inc. earnings are expected to increase by 72.3% in 2021, but the outlook is negative 0% per year for the next five years.
Kintara Therapeutics, Inc. (NASDAQ:KTRA)’s Biggest Investors
Upon looking at major shareholders, it appears that insiders hold 34.43% of Kintara Therapeutics, Inc. shares, and 1.21% of them are in the hands of institutional investors. The stock currently has a share float of 1.84%. Kintara Therapeutics, Inc. stock is held by 15 institutions, with Renaissance Technologies, LLC being the largest institutional investor. By Dec 30, 2020, it held 0.17% of the shares, which is about 40.73 Thousand shares worth $52.14 Thousand.
Two Sigma Investments, LP, with 0.08% or 20.6 Thousand shares worth $28.83 Thousand as of Sep 29, 2020, holds the second largest percentage of outstanding shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.